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ABSTRACT
The t(12;21) (p13;q22) chromosomal translocation resulting in the ETV6/RUNX1 
fusion gene is the most frequent structural cytogenetic abnormality in children with 
acute lymphoblastic leukemia (ALL). The erythropoietin receptor (EPOR), usually 
associated with erythroid progenitor cells, is highly expressed in ETV6/RUNX1 
positive cases compared to other B-lineage ALL subtypes. Gene expression analysis 
of a microarray database and direct quantitative analysis of patient samples revealed 
strong correlation between EPOR and GATA2 expression in ALL, and higher expression 
of GATA2 in t(12;21) patients. The mechanism of EPOR regulation was mainly 
investigated using two B-ALL cell lines: REH, which harbor and express the ETV6/
RUNX1 fusion gene; and NALM-6, which do not. Expression of EPOR was increased 
in REH cells compared to NALM-6 cells. Moreover, of the six GATA family members 
only GATA2 was differentially expressed with substantially higher levels present in 
REH cells. GATA2 was shown to bind to the EPOR 5'-UTR in REH, but did not bind in 
NALM-6 cells. Overexpression of GATA2 led to an increase in EPOR expression in REH 
cells only, indicating that GATA2 regulates EPOR but is dependent on the cellular 
context. Both EPOR and GATA2 are hypomethylated and associated with increased 
mRNA expression in REH compared to NALM-6 cells. Decitabine treatment effectively 
reduced methylation of CpG sites in the GATA2 promoter leading to increased GATA2 
expression in both cell lines. Although Decitabine also reduced an already low level of 
methylation of the EPOR in NALM-6 cells there was no increase in EPOR expression. 
Furthermore, EPOR and GATA2 are regulated post-transcriptionally by miR-362 and 
miR-650, respectively. Overall our data show that EPOR expression in t(12;21) B-ALL 
cells, is regulated by GATA2 and is mediated through epigenetic, transcriptional and 
post-transcriptional mechanisms, contingent upon the genetic subtype of the disease.
INTRODUCTION
The t(12;21) (p13;q22) chromosomal translocation 
occurs in approximately 25% of cases of childhood 
B-lineage acute lymphoblastic leukemia (B-ALL). The 
rearrangement results in the expression of the ETV6/
RUNX1 fusion gene, which leads to increased expression 
of a number of genes, including the erythropoietin receptor 
(EPOR), compared to other subtypes of B-ALL [1–4].
ETV6/RUNX1-positive patients have a favorable 
prognosis but the role of EPOR is poorly understood, as 
is its mechanism of up-regulation in non-erythroid cells. 
In vitro studies have revealed that erythropoietin (EPO) 
enhances proliferation of ETV6/RUNX1-positive cells 
and decreases their sensitivity to prednisone-induced 
apoptosis [5]. ETV6/RUNX1 directly activates the ectopic 
expression of functional EPOR in vitro; leading to the 
suggestion that EPOR signaling may contribute to the 
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persistence of covert premalignant clones in pediatric ALL 
patients with the t(12;21) translocation [6]. In principle 
the increase in EPOR expression in ETV6/RUNX1 
positive cells could arise from complex interactions in 
the regulation of EPOR involving transcription factors, 
CpG methylation status of the EPOR promoter or the 
preponderance of relevant microRNAs (miRNAs).
The expression of EPOR has long been associated 
with hematopoietic cells committed to the erythroid 
lineage. Binding of EPO to EPOR on the surface 
membrane of erythroid progenitors activates the 
intracellular signaling pathways essential for cell survival, 
proliferation and differentiation. Over the last decade it 
has become increasingly clear that EPOR is expressed on 
numerous normal and malignant cell types. Consequently 
recombinant EPO treatment is often withheld from cancer 
patients with anemia, due to the risk of augmenting tumor 
growth [7].
In developing erythroid cells the expression of 
EPOR peaks at the proerythroblast stage [8], concurrent 
with maximal expression of GATA1, an obligatory effector 
of its transcription [9]. Normally, GATA1 is weakly 
expressed in B lymphocytes, therefore this study focused 
on the possible compensatory role of other members of the 
GATA family for the transcriptional regulation of EPOR.
The GATA family of basic-helix-loop-helix 
transcription factors recognizes analogous GATA motifs 
and has six members, of which GATA1, GATA2 and 
GATA3 have important functions in hematopoiesis [10]. 
GATA1 regulates erythropoiesis, megakaryopoiesis 
and the development of eosinophils and mast cells [11]. 
GATA2 is essential for the maintenance and proliferation 
of hematopoietic stem cells and progenitor cells [10, 12]. 
Evidence that GATA2 can also act as a single lineage-
specific transcription factor is provided by Gata2-/- mice 
which have a remarkably specific phenotype in which 
primitive erythropoiesis is strikingly reduced [13].
GATA3 was first identified in a screen for GATA 
factors in the T cell lineage and plays a key role in 
early T cell development and the specification of the 
Th2 subset of T cells [14–16]. A genome-wide germline 
single nucleotide polymorphism (SNP) analysis identified 
variants in the GATA3 gene which influence susceptibility 
to Philadelphia Chromosome-like (Ph-like) ALL and the 
risk of relapse in childhood ALL [17].
Interplay between GATA factors appears to be 
a common mechanism for controlling developmental 
processes [18]. Chromatin occupancy by GATA1 and 
GATA2 changes during hematopoiesis, leading to lineage-
specific differentiation. A recent genome wide analysis 
demonstrated that GATA1 and GATA2 bind overlapping 
sets of genes thereby enabling differential regulation of 
target genes during hematopoiesis [19].
This study examines the mechanisms of EPOR 
up-regulation through GATA2, including its binding 
to the EPOR promoter, CpG methylation status, and 
investigation of miRNAs that inhibit EPOR and GATA2 in 
the two ALL phenotypes.
RESULTS
The expression of EPOR was determined by Q-PCR 
in the B-cell progenitor cell lines REH, which is ETV6/
RUNX1-positive; NALM-6, which is ETV6/RUNX1 
negative and the erythroid cell line, UT-7, known to have 
high EPOR expression, as a positive control. The high 
expression of the ETV6/RUNX1 fusion gene in REH 
cells was confirmed by Q-PCR (Supplementary Figure 
1). EPOR is highly expressed in REH and UT-7 cells 
and significantly (p < 0.001) more weakly expressed in 
NALM-6 cells (Figure 1A). This pattern of expression was 
confirmed by Western blotting (Figure 1B).
EPOR is tightly regulated in erythroid cells, mainly 
by GATA1 which is expressed at low levels in B-cell 
precursors. To investigate whether other members of the 
GATA family are involved in the expression of EPOR, we 
evaluated the expression of each GATA family member 
in the three model cell lines. GATA4, GATA5 and GATA6 
were very weakly expressed in REH and NALM-6 cells, 
and conversely GATA3 was highly expressed in both cell 
lines. However, GATA2 was significantly (p < 0.001) 
differentially expressed, with higher levels in REH than 
in NALM-6 cells (Figure 1C). Western blot analysis 
indicated that GATA2 protein levels were also higher in 
REH than NALM-6 cells (Figure 1D). OCI-AML3 was 
selected as a negative control to check EPOR expression 
in a non-ALL leukemic cell line. Results from the 
Affymetrix datasets confirm that EPOR is substantially 
higher in UT-7 and REH cells than in NALM-6 and OCI-
AML-3 (Supplementary Figure 2).
The expression of EPOR and GATA2 was further 
analyzed in RNA extracted from a cohort of pediatric 
ALL patients, who were either ETV6/RUNX1-positive 
or negative (hyperdiploid ALL). The expression of the 
ETV6/RUNX1 fusion gene in these patient samples was 
confirmed by Q-PCR (Supplementary Figure 3). Figure 
2A shows that patients with the fusion gene had, on 
average, an EPOR expression level 3.96 Ct lower (i.e. 
higher expression) than the ETV6/RUNX1-negative 
(hyperdiploid) patients; this would represent 15.56-fold 
higher expression in EPOR in ETV6/RUNX1-positive 
patients (p < 0.001).
High expression of EPOR was confirmed by 
comparing the gene expression intensities between 
hyperdiploid and ETV6/RUNX1-positive ALL patients 
in the MILE Study (GEO13159) [20], see Figure 2B 
and Supplementary Figure 4A. These data revealed that 
the ETV6/RUNX1-positive ALL patient group had on 
average 3.2-fold higher EPOR expression, compared 
to the hyperdiploid (ETV6/RUNX1-negative) ALL 
patient group (p < 0.001); indicating a strong association 
between ETV6/RUNX1 and EPOR expression in B-cell 
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progenitor cells from ALL patients. The EPOR was 
higher in the ETV6/RUNX1-positive ALL patient group 
than in six other B-ALL subtypes included in the MILE 
study (Supplementary Figure 4B). GATA2 expression 
was also examined in the pediatric ALL cohort, which 
showed the ETV6/RUNX1-positive group had an average 
Ct difference of 4.79, representing 27.67-fold higher 
expression (p < 0.001), Figure 2C.
Figure 2D depicts GATA2 expression, based on 
probeset fluorescence intensity, in hyperdiploid or ETV6/
RUNX1-positive patients in the MILE Study microarray 
data (GEO13159) [20]. GATA2 levels derived from two 
additional probesets were analyzed (Supplementary 
Figure 5). The ETV6/RUNX1-positive ALL patient sub-
group had on average 2.7-fold higher GATA2 expression, 
compared to the ETV6/RUNX1-negative group (p < 
0.001); indicating a strong association between ETV6/
RUNX1 and GATA2 expression in B-cell progenitor cells 
from ALL patients.
A comparison of the expression of EPOR and the 
six GATA binding proteins (GATA1–6) between ETV6/
RUNX1-positive ALL and hyperdiploid ALL patients 
in the MILE study is shown in Table 1. The expression 
of EPOR, GATA2 and GATA3 are significantly higher in 
ETV6/RUNX1-positive ALL than in hyperdiploid ALL 
patients. The lack of GATA1 expression in the cell line 
models, and the increased expression of GATA2 in ETV6/
RUNX1-positive ALL compared to hyperdiploid ALL 
patients suggest that EPOR expression may be regulated 
by GATA2 in this type of B-cell leukemia.
The relationship between EPOR and GATA2 
mRNA levels in individual patient samples showed a 
strong positive correlation between EPOR and GATA2, 
(R = 0.714, p < 0.001) in the pediatric ALL patients with 
Figure 1: EPOR and GATA family members are differentially expressed between ETV6/RUNX1 positive and ETV6/
RUNX1 negative ALL cell lines. (A) The expression of EPOR was analyzed in REH (ETV6/RUNX1 positive), NALM-6 (ETV6/
RUNX1 negative) and UT-7 (EPOR positive control) cells in triplicate by Q-PCR. Expression values were corrected to 18S ribosomal 
RNA levels. Mean corrected Ct values (±SD) are shown and statistical differences to NALM-6 were detected by one-way ANOVA and 
are indicated by *** (p < 0.001). (B) Western blot analysis of EPOR expression in protein extracted from REH, NALM-6 and UT-7 cells. 
GAPDH was used as a loading control. EPOR expression levels were calculated relative to NALM-6 by densitometric analysis using 
GAPDH as a normalization factor. (C) The expression of each GATA family member (GATA1-6) was analyzed in REH, NALM-6 and UT-7 
cells in triplicate by Q-PCR. Expression values were corrected to 18S ribosomal RNA levels. Mean corrected Ct values (±SD) are shown 
and statistical differences to NALM-6 were detected by one-way ANOVA and are indicated by *** (p < 0.001). (D) Western blot analysis 
of GATA2 expression in protein extracted from REH, NALM-6 and UT-7 cells. GAPDH was used as a loading control. GATA2 expression 
levels were calculated relative to NALM-6 by densitometric analysis using GAPDH as a normalization factor.
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ETV6/RUNX1 (Figure 2E). Analysis of the MILE gene 
expression data also revealed a strong positive correlation 
between EPOR and GATA2 mRNA levels (R = 0.614, 
p < 0.001) (Figure 2F). Interestingly 2 of the 58 ETV6/
RUNX1 positive cases in Figure 2F show very low EPOR 
expression and very low GATA2, consistent with the idea 
that GATA2 regulates EPOR. These observations indicate 
that the strict relationship between the high expression 
of EPOR and GATA2 in ETV6/RUNX1 patients is not 
maintained in a minority cases and may reflect phenotypic 
diversity among the 58 patients in this subgroup.
Correlations between each of the EPOR and 
GATA2 probesets from the MILE study are detailed in 
Supplementary Table 3. This provides further evidence in 
support of an interaction between EPOR and GATA2 in the 
presence of ETV6/RUNX1.
To investigate whether EPOR is transcriptionally 
regulated by GATA2, REH and NALM-6 cells were 
transfected with the pENTR221-GATA2 over-expression 
vector. Over-expression of GATA2 mRNA was confirmed 
by Q-PCR in both cell lines 72 hr after transfection. In 
NALM-6 cells, which do not normally express GATA2, 
there was a dramatic increase in GATA2 as indicated by 
an approximately 15,000-fold change (p < 0.001), whilst 
in REH cells, a ≈ 4,000-fold change in expression was 
observed (p < 0.001) (Supplementary Figure 6A). There 
was no significant change in EPOR expression in NALM-
6 cells, but there was a significant increase in EPOR 
Figure 2: EPOR and GATA2 are differentially expressed between ETV6/RUNX1 positive and ETV6/RUNX1 negative 
ALL patients. (A) The expression of EPOR was analyzed in hyperdiploid (N=10) and t(12;21) translocated (N=10) ALL patients by 
Q-PCR. Expression values were corrected to 18S ribosomal RNA levels. (B) EPOR probe intensities (probe ID: 37986_at) of hyperdiploid 
(N=40) and t(12;21) translocated (N=58) MILE study ALL patients extracted after normalization of expression files. (C) The expression of 
GATA2 was analyzed in hyperdiploid (N=9) and t(12;21) translocated (N=10) ALL patients by Q-PCR. Expression values were corrected 
to 18S ribosomal RNA levels. (D) GATA2 probe intensities (probe ID: 209710_at) of hyperdiploid (N=40) and t(12;21) translocated 
(N=58) MILE study ALL patients extracted after normalization of expression files. Whiskers indicate Tukey minimum and maximum 
values; boxes indicate inter-quartile range, with the median marked. Significantly different expression was detected by Student’s t-test 
with Welch’s Correction and indicated by *** (p < 0.001). (E) Correlation between EPOR and GATA2 mRNA expression as measured by 
Q-PCR in patient samples. NOTE: High ΔCt values correspond to low gene expression. Correlation coefficient (r = 0.714) and associated 
p-value (p < 0.001) were calculated by Pearson’s correlation test. (F) Correlation between EPOR (probe ID: 37986_at) and GATA2 (probe 
ID: 209710_at) intensity values in MILE study patient samples. NOTE: High Probe Intensity values correspond to high gene expression. 
Correlation coefficient (r = 0.614) and associated p-value (p < 0.001) were calculated by Pearson’s correlation test.
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expression (Fold change = 13.4, p < 0.001) in REH cells 
(Supplementary Figure 6B). Thus, overexpression of 
GATA2 causes an increase in EPOR expression in REH 
cells, but not in NALM-6, suggesting that additional 
factors necessary for EPOR regulation by GATA2 are only 
present in REH cells.
Chromatin immunoprecipitation (ChIP) analysis 
utilizing both murine and rabbit antibodies revealed that 
GATA2 binds to the EPOR promoter of the genomic locus 
at the most 3´ GATA2 site within the 5´-UTR in REH 
cells, but GATA2 does not bind to the EPOR promoter in 
NALM-6 cells (Figure 3B). This suggested a difference in 
the 5´-UTR of NALM-6 cells that inhibits GATA2 binding 
to the EPOR promoter. An alternative possibility, that the 
low level of GATA2 in NALM-6 cells is insufficient to 
transactivate the EPOR promoter was excluded by the data 
obtained by forced expression of GATA2 (Supplementary 
Figure 6).
The methylation status of eighteen individual CpG 
sites in the EPOR promoter (Figure 4A) of the three 
cell lines was determined by pyrosequencing. The mean 
methylation levels were 35.8%, 5.1% and 4.9% for the 
NALM-6, REH, and UT-7 cells respectively (Figure 
4C). REH and UT-7 cells have comparable levels of 
methylation, less than 20%, at all of the CpG sites 
(Supplementary Figure 7A). In contrast, some of the CpG 
sites in the NALM-6 cells showed substantially higher 
methylation, up to 70%, with 16 sites showing significantly 
higher (p < 0.001) levels than the corresponding CpG 
sites in REH and UT-7 cells. Pyrosequencing of five 
CpG sites in the GATA2 upstream region (Figure 4B) 
revealed mean methylation levels of 59.6% for NALM-6, 
13.8% for REH, and 10.28% for UT-7 cells (Figure 4D); 
significantly higher methylation was found at all sites in 
the NALM-6 than in either REH or UT-7 cells (p < 0.001; 
Supplementary Figure 7B). The lower expression of both 
Table 1: Expression of EPOR and GATA binding proteins in t(12;21) ALL and hyperdiploid ALL from the MILE Study
  Probeset ID Gene symbol Gene title 
ALL with t(12;21) vs. ALL hyperdiploid
p Value Fold change Higher in
Probeset E1 37986_at EPOR erythropoietin receptor 2.98E-21 2.95025 ALL with t(12;21)
Probeset E2 215054_at EPOR erythropoietin receptor 1.74E-20 2.8498 ALL with t(12;21)
Probeset E3 209962_at EPOR erythropoietin receptor 8.69E-18 3.35594 ALL with t(12;21)
Probeset E4 209963_s_at EPOR erythropoietin receptor 2.08E-10 1.899 ALL with t(12;21)
Probeset E5 396_f_at EPOR erythropoietin receptor 5.63E-05 1.30265 ALL with t(12;21)
Probeset E6 216999_at EPOR erythropoietin receptor 0.183499 -1.02559  
Probeset G1.1 1555590_a_at GATA1 GATA binding protein 1 0.558919 -1.03024  
Probeset G1.2 210446_at GATA1 GATA binding protein 1 0.939326 1.00597  
Probeset G2.1 209710_at GATA2 GATA binding protein 2 2.47E-12 2.68299 ALL with t(12;21)
Probeset G2.2 210358_x_at GATA2 GATA binding protein 2 1.27E-07 1.28291 ALL with t(12;21)
Probeset G2.3 207954_at GATA2 GATA binding protein 2 0.460004 1.01988  
Probeset G3.1 209604_s_at GATA3 GATA binding protein 3 3.70E-05 2.15746 ALL with t(12;21)
Probeset G3.2 209602_s_at GATA3 GATA binding protein 3 0.00157696 1.45584 ALL with t(12;21)
Probeset G3.3 209603_at GATA3 GATA binding protein 3 0.0263834 1.19443 ALL with t(12;21)
Probeset G4.1 230855_at GATA4 GATA binding protein 4 0.11158 1.06661  
Probeset G4.2 1570276_a_at GATA4 GATA binding protein 4 0.243658 -1.02736  
Probeset G4.3 205517_at GATA4 GATA binding protein 4 0.267507 -1.02403  
Probeset G4.4 243692_at GATA4 GATA binding protein 4 0.317532 -1.03456  
Probeset G4.5 1553131_a_at GATA4 GATA binding protein 4 0.794327 -1.00928  
Probeset G5.1 238095_at GATA5 GATA binding protein 5 0.591853 -1.01384  
Probeset G5.2 238197_at GATA5 GATA binding protein 5 0.872993 1.00297  
Probeset G6.1 229282_at GATA6 GATA binding protein 6 0.169085 -1.06536  
Probeset G6.2 210002_at GATA6 GATA binding protein 6 0.20102 -1.03821  
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EPOR and GATA2 seen in NALM-6 cells, compared to 
REH and UT-7 cells, is consistent with the concept that 
epigenetic silencing of genes is frequently associated with 
hypermethylation of the promoter region.
We investigated the effect of Decitabine on the 
EPOR promoter in NALM-6 cells, see Supplementary 
Figure 8A. Of the 18 CpG sites analyzed, 15 showed 
statistically significant decreases in methylation after 
treatment with Decitabine in the range 50 to 500 nM. CpG 
sites 7, 8 and 18 have low DNA methylation status which 
did not change upon Decitabine treatment. No significant 
changes in methylation status of the EPOR promoter were 
found in REH cells after treatment with Decitabine, see 
Supplementary Figure 9A.
The effect of Decitabine on the GATA2 promoter 
methylation status in NALM-6 cells is shown in 
Supplementary Figure 8B. Decitabine in the range 50 
to 500 nM caused significant reductions in percentage 
methylation at all five of the CpG sites. The effect of 
Decitabine on GATA2 promoter methylation status was 
less marked in REH cells (Supplementary Figure 9B). 
Decitabine in the range 50 to 500 nM caused significant 
upregulation of GATA2 expression in both REH and 
NALM-6 cells. In contrast the changes in EPOR 
expression were minimal in both cell lines, see Figure 5.
MicroRNAs are a class of epigenetic regulatory 
molecules that act at the post-transcriptional level to 
repress target genes by inhibition of translation and 
destabilization of mRNA [21]. Twenty-two miRNAs 
were predicted to target EPOR based on data collated 
from the Pareto Front predictive algorithm, the publicly 
available ‘miRecords’ target prediction meta-database, and 
a strongly negative “Probability of Interaction by Target 
Accessibility” (PITA) score (Figure 6A, Supplementary 
Methods, and Supplementary Table 4). Of these only 
miR-362-5p showed an overlap with those significantly 
up-regulated in NALM-6 cells (labeled in Figure 6C). 
Similarly, 21 miRNAs were predicted to target GATA2 
based on the same criteria (Figure 6B and Supplementary 
Table 4). Of these only miR-650 was significantly up-
Figure 3: GATA2 binds to the 5′ UTR region of the EPOR gene in REH, but not NALM-6, cells. (A) Schematic of the 
EPOR genomic locus showing the relative positions of predicted GATA2 binding sites (↓), the EPOR transcription start site (TCSS), the 
EPOR translation start site (TLSS) and the amplicon targets in ChIP experiments. All genomic coordinates are given relative to the TCSS. 
(B) ChIP assays were performed on formaldehyde-fixed chromatin prepared from REH and NALM-6 cells. Enrichment of GATA2 binding 
to EPOR 5′ DNA was determined by comparison to a non-specific binding region and input chromatin controls. Two independent GATA2 
antibodies were used. GATA2 binding enrichment was assessed at four genomic loci (Amplicon 1-4). Significant enrichments were detected 
by two-way ANOVA with Bonferroni’s post-hoc test and are indicated by *** (p < 0.001).
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Figure 4: The EPOR and GATA2 5′ DNA is highly methylated in NALM-6, but not in REH cells. (A) Schematic of the 
EPOR genomic locus showing the relative positions of CpG dinucleotides (  ), the EPOR transcription start site (TCSS), the EPOR translation 
start site (TLSS) and the CpG sites included in the pyrosequencing assay (grey dashed box). All genomic coordinates are given relative to 
the TCSS. (B) Schematic of the GATA2 genomic locus showing the relative positions of CpG dinucleotides (  ), the GATA2 transcription 
start site (TCSS) and the CpG sites included in the pyrosequencing assay (grey dashed box). (C) EPOR 5′ DNA specific pyrosequencing 
assays were performed on bisulphite converted DNA prepared from REH, NALM-6 and UT-7 cells. DNA methylation was assessed at 18 
CpG sites in triplicate. Whiskers indicate Tukey minimum and maximum CpG methylation values; boxes indicate inter-quartile range, with the 
median marked. Significant enrichments were detected by one-way ANOVA and are indicated by *** (p < 0.001). (D) GATA2 5′ DNA specific 
pyrosequencing assays were performed on bisulphite converted DNA prepared from REH, NALM-6 and UT-7 cells. DNA methylation was 
assessed at 5 CpG sites in triplicate. Whiskers indicate Tukey minimum and maximum CpG methylation values; boxes indicate inter-quartile 
range, with the median marked. Significant enrichments were detected by one-way ANOVA and are indicated by *** (p < 0.001).
●  
● 
Figure 5: Decitabine causes demethylation of both EPOR and GATA2 but only increases expression of GATA2. EPOR 
and GATA2 expression in REH and NALM-6 cells after treatment with 50 to 500 nM Decitabine. Expression values were corrected to 18S 
ribosomal RNA levels. Mean corrected Ct values (±SD) are shown. Statistical differences compared to the control (0 nM Decitabine) are 
indicated by * (p < 0.05), ** (p < 0.01), or *** (p < 0.001) were calculated with the two-way ANOVA with Holm Sidak correction.
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regulated (labeled in Figure 6C). To investigate the 
miRNA profiles in REH and NALM-6 cells Taqman® 
microRNA arrays were performed in triplicate. The arrays 
allow simultaneous analysis of 667 miRNAs and showed 
that 11 miRNAs were significantly up-regulated and 20 
miRNAs were significantly down-regulated in NALM-6 
cells compared to REH cells (Figure 6C). Expression data 
obtained from microRNA array analysis were validated by 
single assay Q-PCR which confirmed that the expression 
of both miR-362 and miR-650 are higher in NALM-6 than 
in REH cells (Figure 6D).
miR-362-5p, predicted to target EPOR, was over-
expressed in REH cells, confirmed by Q-PCR, (Figure 7A 
& 7B) and a modest, but not significant, decrease in EPOR 
mRNA expression was observed after 72 hr. However, a 
four-fold decrease in EPOR protein levels was observed 
at 72 hr post-transfection with miR-362-5p (Figure 7C). 
These data suggest that miR-362-5p can regulate EPOR 
expression in REH cells. The overexpression of miR-650, 
predicted to target GATA2, in REH cells was confirmed 
by Q-PCR (Figure 7D & 7E). Both GATA2 and EPOR 
mRNA and protein expression were examined at 24 hr 
and 72 hr post-transfection. A decrease in GATA2 mRNA 
was observed after 72 hr, but did not reach statistical 
significance; however, a seven-fold decrease in GATA2 
protein was found after 72 hr. EPOR expression of both 
mRNA and protein decreased by approximately 30% at 
72 hr post-transfection with miR-650. Overall our data 
suggest that miR-650 regulates GATA2 protein expression 
and as a consequence EPOR expression whilst miR-362-
5p regulates EPOR expression in REH cells.
Figure 6: Expression of microRNAs predicted to target EPOR and GATA2 are increased in NALM-6 cells. (A) 
Venn diagram showing consensus between an in silico microRNA targeting algorithm [45] and publicly available prediction databases. 
MicroRNAs predicted to target EPOR were selected and overlapped. (B) Venn diagram showing consensus between an in silico microRNA 
targeting algorithm [45] and publicly available prediction databases. MicroRNAs predicted to target GATA2 were selected and overlapped. 
(C) Volcano plot of the differential expression of microRNAs between REH and NALM-6 cells and the associated nominal p-value. The 
expression of 670 microRNAs was analyzed in REH and NALM-6 cells in triplicate by Q-PCR using multiplex assays. Expression values 
were corrected to the mean RNU6 and RNU44 levels. Nominal p-values associated with the fold differences compared to NALM-6 were 
determined using the Bioconductor package ‘limma’. Selection criteria for significantly different expression were an absolute fold change 
≥5 and a nominal p-value < 0.05. (D) The differential expression of selected microRNAs (miR-362-5p and miR-650) was validated in REH 
and NALM-6 cells in triplicate by Q-PCR using single microRNA assays. Expression values were corrected to the mean RNU6 and RNU44 
levels. Mean relative expression levels (±SD) compared to REH are shown and statistical differences to REH were detected by two-way 
ANOVA and are indicated by * (p < 0.05) or *** (p < 0.001).
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DISCUSSION
The EPOR promoter is unusual because it lacks 
a TATA box in the core promoter region, but it does 
contain functional SP-1 and GATA binding sequences. 
SP-1 is a ubiquitous transcription factor unlikely to drive 
lineage-specific expression of EPOR. Since GATA1 is an 
obligatory transcription factor for EPOR expression in 
erythroid cells, but is expressed at extremely low levels 
in B cell progenitors, it was important to determine if 
other members of the GATA family might contribute 
to the increased expression of EPOR found in ETV6/
RUNX1-positive cells. Of the six GATA family members 
only GATA2 was found to be differentially expressed with 
substantially higher levels present in REH cells, i.e. those 
with the t(12;21) translocation.
GATA2 has a pivotal role in hematopoietic stem 
and progenitor cell development and its expression 
Figure 7. Forced expression of miR-362-5p and miR-650 reduces EPOR and GATA2 expression. (A) The expression of 
miR-362-5p and EPOR were analyzed in REH cells in triplicate by Q-PCR 24 hr post-transfection with a miR-362-5p expression vector. 
Expression values were corrected to 18S ribosomal RNA levels. Mean relative expression levels (±SD) compared to empty vector controls 
are shown and statistical differences to control were detected by one-way ANOVA and are indicated by *** (p < 0.001). (B) The expression 
of miR-362-5p and EPOR were analyzed in REH cells in triplicate by Q-PCR 72 hr post-transfection with a miR-362-5p expression vector. 
Expression values were corrected to 18S ribosomal RNA levels. Mean relative expression levels (±SD) compared to empty vector controls 
are shown and statistical differences to control were detected by one-way ANOVA and are indicated by *** (p < 0.001). (C) Western blot 
analysis of EPOR expression in protein extracted from REH cells 24 hr. and 72 hr. post-transfection with a miR-362-5p expression vector. 
GAPDH was used as a loading control. EPOR expression levels were calculated relative to htR (EV control) by densitometric analysis using 
GAPDH as a normalization factor. (D) The expression of miR-650, EPOR and GATA2 were analyzed in REH cells in triplicate by Q-PCR 
24 hr. post-transfection with a miR-650 mimetic oligo. Expression values were corrected to 18S ribosomal RNA levels. Mean relative 
expression levels (±SD) compared to scrambled oligo controls are shown and statistical differences to control were detected by one-way 
ANOVA and are indicated by *** (p < 0.001). (E) The expression of miR-650, EPOR and GATA2 were analyzed in REH cells in triplicate 
by Q-PCR 72 hr. post-transfection with a miR-650 mimetic oligo. Expression values were corrected to 18S ribosomal RNA levels. Mean 
relative expression levels (±SD) compared to scrambled oligo controls are shown and statistical differences to control were detected by 
one-way ANOVA and are indicated by *** (p < 0.001). (F) Western blot analysis of EPOR and GATA2 expression in protein extracted from 
REH cells 24 hr. and 72 hr. post-transfection with a miR-650 mimetic oligo. GAPDH was used as a loading control. EPOR and GATA2 
expression levels were calculated relative to scrambled oligo control by densitometric analysis using GAPDH as a normalization factor.
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decreases with differentiation implying that GATA2 is 
necessary to maintain pluripotency [22]. The data indicate 
that GATA2 is a regulator of the EPOR gene in t(12;21) 
B cell ALL. This is supported by pediatric t(12;21) ALL 
patients and ETV6/RUNX1-positive cells having both 
highly expressed levels of EPOR and GATA2 with a 
strong positive correlation. This trend was confirmed by 
in silico analysis of the MILE expression profiling data 
(GSE13159) which showed that GATA2 was more highly 
expressed and exhibits a stronger correlation with EPOR 
expression in ALL patients with the t(12;21) translocation.
High GATA2 expression is a poor prognostic marker 
in pediatric myeloid leukemia. Following chemotherapy 
GATA2 was found to be normalized in patients in complete 
remission but remained high in those with resistant 
disease [23]. Recently it has been reported that reduction 
of GATA2 by shRNA or the inhibitor K7174 sensitizes 
KG1a acute myeloid leukemia cells to chemotherapy 
[24], suggesting that suppression of GATA2 expression or 
inhibition of its transcriptional activity may have potential 
as an ancillary therapy in AML.
GATA2 is overexpressed in acute myeloid leukemia 
(AML) and loss-of-function mutations have been 
causally linked to immunodeficiency associated with the 
myelodysplastic syndromes (MDS), suggesting that an 
appropriate level of GATA2 activity is a prerequisite for 
normal hematopoiesis [25]. The role of GATA2 as a tumor 
suppressor remains to be defined. Vicente and colleagues 
have proposed a transcriptional network involved in 
the emergence of hematopoietic stem cells in which 
GATA2, FLI1 and SCL form a complex that is recruited 
to the RUNX1 enhancer, activating its transcription [25]. 
Mutations in any of the constituent genes may perturb this 
regulatory system and alter the phenotype of the daughter 
cells.
A mechanistic link between RAS, which harbors 
activating mutations in 30% of all human cancers, and 
GATA2 has recently been uncovered [26]. Downstream 
from RAS, MAPK p38 phosphorylates a number of 
residues in GATA2, the most critical of which is S192, 
leading to GATA2 transcriptional activity. In this context 
GATA3 has also been found to promote cycling of 
hematopoietic stem cells and to restrict the long-term 
reconstitutive potential downstream of p38 in stress-
induced hematopoiesis [27]. GATA2 transcription is 
regulated by several transcription factors including ETS1, 
BMP4, NOTCH1, PU.1 and EVI1 (reviewed by Vicente 
[25]). The regulatory elements also contain GATA motifs 
so that GATA2 expression is regulated both by itself and 
by GATA1.
The UT-7/Epo sub-line was derived through 
continuous long-term culture of the human leukemic cell 
line UT-7 in the presence of EPO [28]. The higher levels of 
GATA1 mRNA found in UT-7/Epo compared to UT-7 cells 
indicated that the cells of the sub-line were committed to 
the erythroid lineage. Apart from the special case of UT-7/
Epo cells there is little evidence that EPO can stimulate 
leukemic cell proliferation, though in principle survival 
and proliferation of leukemic cells could be enhanced by 
presence of functional EPO receptors.
Beyond the hematopoietic compartment EPO can 
induce GATA3 and GATA4 leading to the up-regulation 
of EPOR expression. Thus EPO stimulation of myoblasts 
causes up-regulation of GATA3, GATA4 and another 
basic-helix-loop-helix factor, TAL1. In turn, these 
transcription factors up-regulate EPOR expression in the 
myoblast [29, 30]. Moreover EPOR expression in neural 
NT2 cells can be trans-activated by GATA3, which is 
required for brain development [31]. These observations 
highlight the ability of different GATA factors to trans-
activate the erythropoietin receptor in the context of 
cellular phenotype.
The different genetic sub-types of ALL can be 
characterized by distinct DNA methylation signatures 
that demonstrate significant correlation with expression 
profiles [32]. EPOR was one of sixteen genes found to be 
specifically hypo-methylated in the t(12;21) subtype and 
associated with increased mRNA expression [33]. Higher 
methylation of one CpG site in GATA2 was found in sub-
types of ALL, compared to controls, but no difference 
was found between the t(12;21) and hyperdiploid sub-
types [34].
In the present work, GATA2 was found to bind 
to EPOR downstream of the transcriptional start site in 
REH cells but not in NALM-6 cells and overexpression 
of GATA2 increased EPOR production only in REH 
cells, supporting the suggestion that other regulatory 
mechanisms are involved. DNA methylation analysis 
of EPOR showed approximately 7-fold higher levels of 
methylation in the ETV6/RUNX1-negative NALM-6 
cells compared to REH and UT-7. Methylation of 15 of 
18 CpGs located 5' of the EPOR promoter was higher 
in NALM-6 than in REH cells, but one of the three 
exceptions was the most proximal CpG to the GATA 
binding site identified by ChIP. Similarly the GATA2 
promoter region of NALM-6 showed 4- and 5-fold higher 
levels of methylation compared to REH and UT-7 cells 
respectively.
Decitabine caused significant demethylation of 15 
of the 18 CpG sites analyzed on the EPOR promoter in 
NALM-6 cells, but this did not lead to increased EPOR 
expression. Similarly, Decitabine reduced an already 
low level of methylation of the EPOR promoter in REH 
cells, but did not cause increased EPOR expression. 
Decitabine caused significant reductions in methylation 
of all five CpG sites analyzed in the GATA2 promoter in 
both NALM-6 and REH cells and led to increased GATA2 
expression in both cell lines.
MicroRNAs are short non-coding RNA molecules of 
19-25 nucleotides with the capacity to regulate genes post-
transcriptionally by silencing specific gene expression and 
inhibiting protein translation [21]. miRNAs are involved 
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in a wide range of biological processes, and can function 
as instructive determinants of cell fate during ontogeny. 
miRNAs are frequently dysregulated in human cancers, 
including leukemia: some exert tumor suppressive effects 
while others promote cancer progression by enhancing 
tumor growth, angiogenesis, invasion and immune evasion 
[35]. A global reduction in miRNA expression has been 
found in cancer and different types of leukemia [36].
Deletion models show that miRNAs are essential 
regulators of hematopoietic stem and progenitor cell 
survival, differentiation and function [37]. miRNAs can 
function as instructive determinants of cell fate during 
ontogeny. miR-142-3p is absolutely conserved across 
vertebrates and modulates the maturation of myeloid, 
erythroid and T cell lineages. Recent work indicates 
that miR-142-3p functions as a master regulator of HSC 
specification in Xenopus development by controlling a 
growth regulatory network which includes tgfbr1, fli1 and 
gata2 [38].
miRNAs which were significantly differentially 
expressed between REH and NALM-6 cells were 
compared to those predicted by miRecords and Pareto 
Front analysis to identify those likely to cause down-
regulation of EPOR and GATA2. Overexpression of miR-
362 caused down-regulation of EPOR protein levels. 
Similarly, overexpression of miR-650 caused down-
regulation of both GATA2 and EPOR, providing further 
evidence for a functional relationship between GATA2 and 
EPOR.
The exact roles of mir-362 and mir-650 in the 
growth regulatory networks of hematopoietic cells and 
in the genetic sub-types of leukemic cells remain to be 
defined. Whereas both microRNAs are differentially 
expressed in the REH and NALM-6 cell line models, 
neither was found to be differentially expressed when 
seven subtypes of ALL were compared in a comprehensive 
study of 81 childhood cases using 397 microRNAs [39].
It is of interest that mir-362 is up-regulated by EPO 
in UT-7 cells [40], which suggests that mir-362 forms 
part of a feedback loop to downregulate EPOR following 
EPO-induced activation of the receptor. miR-362-5p 
has also been reported to act as an oncomiR by down-
regulating GADD45α, which in turn activated the JNK1/2 
and P38 signaling in CML patient samples [41]. miR-650 
has been reported to target proteins important for B cell 
proliferation and survival and to affect the biology of 
chronic lymphocytic leukemia [42].
The GATA gene family activates and represses 
target genes through multiple mechanisms in a context-
dependent manner (reviewed by Bresnick [18]). The 
present work has provided evidence that GATA2 can up-
regulate EPOR in ETV6/RUNX1 positive sub-type of 
B-ALL. This up-regulation occurs via a complex series of 
epigenetic, transcriptional, and post-transcriptional events 
which are context-dependent. However, the elucidation of 
these relationships between GATA2 and EPOR in other 
subtypes of B-ALL will be required to determine their 
clinical and therapeutic potential.
MATERIALS AND METHODS
Cell lines and patient samples
Details of the cell lines and culture conditions are 
shown in Supplementary Methods and Supplementary 
Table 1. Gene expression data were extracted from the 
Microarray Innnovations in LEukemia (MILE) Study [20], 
Gene Expression Omnibus accession number GSE13159.
RNA and DNA extraction
Total RNA and genomic DNA were isolated using 
the RNeasy Mini Kit and the DNeasy Blood and Tissue 
Kit (Qiagen). Purity and concentration were evaluated 
using a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific). RNA was prepared from bone marrow of ALL 
patients [43].
MicroRNA extraction and array analysis
Total RNA was extracted using mirVana™ miRNA 
Isolation kits (Ambion). The Taqman® MicroRNA 
Reverse Transcription kit and Megaplex™ RT Primers 
(Applied Biosystems) were used to synthesize ss-cDNA. 
MicroRNAs were quantified using Taqman® Human 
microRNA array cards (Applied Biosystems) and Partek-
GSS. Target prediction was performed using miRecords 
[44] and Pareto Front analysis software [45]. Validation 
assays were performed using Taqman® MicroRNA 
Assays.
Quantitative real-time PCR (Q-PCR)
Cell-line cDNA was generated using M-MLV 
Reverse Transcriptase (Invitrogen). Patient cDNA was 
generated using Superscript III First Strand Synthesis 
System (Invitrogen). Q-PCR was performed on 
the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). EPOR and GATA1-6 expression was 
measured using Taqman probes (Applied Biosystems). 
ETV6/RUNX1 fusion expression was measured using 
SYBR Green primers (Roche; available on request).
Pyrosequencing (Qiagen)
Primers were designed using PyroMark Assay 
Design 2.0 software (Supplementary Table 2). Genomic 
DNA was deaminated using an EpiTect Bisulfite Kit and 
complete conversion checked by Calponin PCR [46]. 
Regions of interest were amplified using the PyroMark 
PCR kit before pyrosequencing on a Q24 Instrument 
(Qiagen).
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Decitabine treatment of cells
To 3x106 REH or NALM-6 cells 5-Aza-2'-
deoxycytidine (Decitabine; Sigma-Aldrich) was added to 
give final concentrations of 50 nM, 150 nM, 350 nM and 
500 nM. Water served as the untreated control. After each 
48 hour interval the cells were pelleted and resuspended 
in 3 ml of media and freshly prepared Decitabine. After 7 
days, the period required for four doublings for each cell 
line, pellets prepared from 1.5 ml of each cell suspension 
were used for RNA and DNA extraction.
Protein extraction and western blotting
Protein, extracted using RIPA buffer and quantitated 
using the Pierce BCA Protein Assay, was resolved by SDS-
PAGE (12%). Protein was transferred to nitrocellulose 
membrane (Sigma), incubated with anti-EPOR, anti-
GATA2, or anti-GAPDH antibodies overnight at 4°C and 
visualized using Advansta WesternBright ECL (MyBio). 
Band density was analyzed using Li-Cor Image Studio Lite 
version 4.0. The EPOR antibody was a murine monoclonal 
obtained from Abnova cat no: H00002057-M01. The 
GATA2 antibody was a rabbit polyclonal obtained from 
Abcam cat no: ab22849.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as 
previously described [47]. Briefly, chromatin was isolated 
from formaldehyde-cross-linked REH and NALM-6 
cells, sheared by sonication and immunoprecipitated 
overnight with anti-GATA2 antibodies bound to magnetic 
beads (Invitrogen). Isolated complexes were washed 
before reversal of the DNA-protein cross-linking and 
DNA purification by QIAquick columns (Qiagen). DNA 
was subjected to Q-PCR analysis with gene promoter or 
non-specific region primers to evaluate promoter DNA 
enrichment.
Over-expression of GATA2, miR-650  
(pre-miR-650) and miR-362
Cells were seeded 24 hr. before transfection with 
2 μg of negative control (pENTR221-β-glucuronidase), 
GATA2 (pENTR221-GATA2) or GFP vector using an 
Amaxa Nucleofector I Device. Nucleofector Kit T and 
Kit R (Lonza) were used to transfect NALM-6 and REH 
respectively. At 72 hr. samples were taken for Q-PCR or 
western blot. REH cells were transfected with 30 nM pre-
miR-650 (Ambion) or FAM-labeled Pre-mir Negative 
Control #1 (Applied Biosystems). Identical methods were 
used to transfect with miR-362 or control htr vectors 
[48] obtained from the Human miRNA Library (Source 
BioScience).
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